Allianz Asset Management GmbH Has $10.80 Million Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Allianz Asset Management GmbH reduced its stake in Teva Pharmaceutical Industries by 5.1%, holding approximately 644,076 shares valued at $10.80 million as of its latest SEC filing.
• Teva reported quarterly earnings of $0.66 EPS, surpassing estimates, although revenue of $4.18 billion fell short of analyst expectations of $4.34 billion.
• Research analysts have mixed ratings for Teva, with targets raised by UBS and JPMorgan to $26.00, while Weiss Ratings reiterated a "sell" rating, resulting in a consensus "Buy" rating among analysts.

Allianz Asset Management GmbH decreased its holdings in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 5.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 644,076 shares of the company's stock after selling 34,916 shares during the quarter. Allianz Asset Management GmbH owned approximately 0.06% of Teva Pharmaceutical Industries worth $10,795,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Golden State Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 1st quarter worth $39,000. New Age Alpha Advisors LLC acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at $43,000. Sound Income Strategies LLC grew its stake in Teva Pharmaceutical Industries by 3,715.8% in the 2nd quarter. Sound Income Strategies LLC now owns 2,900 shares of the company's stock valued at $49,000 after buying an additional 2,824 shares during the last quarter. Banque Cantonale Vaudoise acquired a new position in Teva Pharmaceutical Industries in the 1st quarter valued at $74,000. Finally, CWM LLC grew its stake in Teva Pharmaceutical Industries by 18.1% in the 2nd quarter. CWM LLC now owns 4,995 shares of the company's stock valued at $84,000 after buying an additional 767 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $19.01 on Wednesday. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. The firm has a market capitalization of $21.80 billion, a price-to-earnings ratio of -118.78, a P/E/G ratio of 1.07 and a beta of 0.71. The company's fifty day moving average is $19.00 and its two-hundred day moving average is $17.18. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business's quarterly revenue was up .3% on a year-over-year basis. During the same period last year, the business posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Activity

In other news, insider Placid Jover sold 6,053 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $91,763.48. Following the sale, the insider directly owned 6,774 shares in the company, valued at approximately $102,693.84. The trade was a 47.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric A. Hughes sold 52,742 shares of Teva Pharmaceutical Industries stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total transaction of $799,568.72. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research note on Saturday, October 11th. UBS Group raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, September 24th. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an "overweight" rating in a research note on Friday, October 3rd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $25.57.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.